Shield Therapeutics Plc (LSE:STX) has spent four years sharing the Economics of its only marketed product with a much larger partner. From 30 September 2026 that ends. On 27 August the specialty pharmaceutical company announced it will take full commercial control of ACCRUFeR, its oral iron therapy, in the United States, swapping a 45% Revenue share owed to Viatris for a Royalty starting in the high single digits.
The deal lands a week after interim results showing Shield's first operating profit, and a month after the shares hit a 52-week low of 3.70p. With the stock at around 6p and a Market Value of roughly £64m, the question is whether a Business generating $30m of half-year revenue and about to keep all of its US Gross Profit is being priced for the risks rather than the rewards.
Latest development: Shield takes ACCRUFeR back from Viatris
The 27 August announcement is the biggest strategic change at Shield since Viatris joined as US commercialisation partner in 2022. Shield assumes control of the entire US sales organisation the two companies previously ran jointly, together with pricing, market access, promotional strategy and first-party data on prescribers, payors and patients.
There is no upfront payment to Viatris. Instead Shield will pay a royalty on US net sales ranging from "high single digits in early years to the mid-teens" over five years. Set against the 45% revenue share reflected in H1 2026 cost of sales, the company calls the transaction "immediately accretive" and says it enhances its expectation of operating profitability in 2026 through greater net sales retention, stronger margins and improved cash generation.
Chief executive Anders Lundstrom called the move "an important strategic milestone for Shield", adding that "with full control across strategy, execution and economics" the company is "very well positioned to accelerate value creation". Management also frames the US infrastructure as a platform for additional products.
Business overview: one product, a growing global footprint
Shield Therapeutics is a commercial-stage pharmaceutical company built around ferric maltol, sold as ACCRUFeR in the US and FeRACCRU in Europe. The company describes it as the first and only FDA-approved oral iron therapy for iron deficiency and the number one branded prescription oral iron in the US. Patent coverage runs into the mid-2030s, and in February 2026 the FDA granted additional exclusivity following the paediatric extension.
The US is by far the largest market. Elsewhere Shield licenses the product: Norgine sells FeRACCRU in Europe, KYE Pharmaceuticals launched in Canada in March 2025, ASK Pharma is the partner in China, where the NMPA accepted a Marketing application in March 2026, and a Korean licensee received authorisation in November 2025. A Japanese Phase II trial began enrolling in April 2026. Partners pay royalties and milestones that supplement US sales.
The label is widening too. The FDA approved use in children aged ten and over on 1 April 2026, with European and UK approvals for adolescents following in May and July.
Latest financial performance: first operating profit in H1 2026
Interim results for the six months to 30 June 2026, published on 20 August, showed total revenue of $30.4m, up 42% from $21.4m in H1 2025. US ACCRUFeR net sales rose 5% to $20.1m, held back by a lower average net price of $199 per prescription against $214 a year earlier, even though prescriptions grew 21% to around 102,000. The commercially insured segment, two-thirds of revenue, grew 27%. Ex-US royalties and milestones jumped to $10.3m from $2.2m, driven by a $7.9m development milestone from ASK Pharma.
Gross profit rose to $18.1m from $10.6m and gross Margin improved to 59.7% from 49.4%. Operating profit was $0.2m, against a $5.8m operating loss in H1 2025. After finance costs the loss before tax narrowed to $2.1m from $9.4m, with a net loss of $2.3m and Basic Earnings Per Share of nil cents versus a 1 cent loss.
The Balance Sheet is thinner than the profit line. Cash was $8.3m at 30 June 2026, down from $11.6m at 31 December 2025. Shield had drawn $24.9m of a $25m Runway Growth Capital Facility maturing on 28 September 2028, plus $11.1m of receivables financing and $3.1m of a deferred AOP Shareholder loan. Net liabilities were $17.0m, though the directors concluded the company has sufficient cash for at least twelve months and adopted the going-concern basis.
Full-year 2025 revenue was $49.7m, up from $32.2m in 2024, with a loss before tax of $17.1m. Management reiterated in August that it remains "on track for operating profitability in 2026".
What could drive the stock next?
The most immediate catalyst is the first full quarter of US sales under Shield's own control. A Q3 trading update, likely in October if the company follows its recent pattern, will only capture the transition, but Q4 will show what swapping a 45% revenue share for a single-digit royalty does to margins.
Prescription Volume is the second lever. The first group purchasing organisation contract opens access to more than 400 hospital-affiliated clinics, and the paediatric indication adds a new patient pool. Management is targeting launches in China and Korea in 2027, and an NMPA approval in China would advance the ASK partnership. New CFO Michael Jensen, who joined on 1 September 2026, arrives as the company argues its US infrastructure can carry additional products; any in-licensing deal would test that thesis.
Risks investors should watch
Liquidity is the obvious concern. With $8.3m of cash, secured and receivables Debt and a history of dilutive raises, including a £1.5m placing in September 2025, any slip on the path to sustained profitability could require fresh capital at a low share price. The Runway facility carries a minimum Liquidity covenant and interest at Term SOFR plus 8.75%, and its interest-only period ends in 2027.
Shield will also now bear the full cost and execution risk of a US sales force it previously shared, while the net price per prescription has been falling: H1 US net sales grew only 5% despite 21% prescription growth. Dependence on a single product, lumpy partner milestones such as the $7.9m ASK payment, and competition from cheap over-the-counter iron and intravenous alternatives round out the risks. Reporting in dollars while listed in sterling adds currency noise for UK holders.
Outlook
Shield Therapeutics (LSE:STX) enters the final third of 2026 with a first operating profit, a widening label and a US commercial deal that materially changes its economics from 30 September. The shares' recovery from August's low has been modest relative to the scale of that change, which may reflect the balance sheet as much as scepticism about the product.
The next two trading updates will show whether retaining US gross profit translates into the cash generation management is promising. Investors should watch prescription growth, net price per prescription, cash against debt covenants, and progress on Chinese approval and 2027 launches. Whether the market is underestimating the story will depend on those numbers, not the narrative.






Please wait processing your request...